https://www.selleckchem.com/pr....oducts/caerulein.htm
23 [95% CI, 0.02-2.54]; p = .23). Compared to NSM, VP/BKP reduces the 12-month risk of all-cause mortality and morbidity by 19% and 36%, respectively. Moreover, VP/BKP reduces by 77% the 12-month risk of infection from any origin. • Compared to non-surgical management, vertebral augmentation reduces the 12-month risk of all-cause mortality by 19% and all-cause morbidity by 36%. • Vertebral augmentation reduces the 12-month risk of infection morbidity from any origin by 77%. • Compared to non-surgical management, vertebral augmentation
Like
Comment
Share
